Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35679021

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Clin Cancer Res
Publication date
2022 Oct 3
First author
Duke ES

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Duke ES
      type
      Author
    2. name
      Barone AK
      type
      Author
    3. name
      Chatterjee S
      type
      Author
    4. name
      Mishra-Kalyani PS
      type
      Author
    5. name
      Shen YL
      type
      Author
    6. name
      Isikwei E
      type
      Author
    7. name
      Zhao H
      type
      Author
    8. name
      Bi Y
      type
      Author
    9. name
      Liu J
      type
      Author
    10. name
      Rahman NA
      type
      Author
    11. name
      Wearne E
      type
      Author
    12. name
      Leighton JK
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Duke ES
      type
      Author
    2. name
      Barone AK
      type
      Author
    3. name
      Chatterjee S
      type
      Author
    4. name
      Mishra-Kalyani PS
      type
      Author
    5. name
      Shen YL
      type
      Author
    6. name
      Isikwei E
      type
      Author
    7. name
      Zhao H
      type
      Author
    8. name
      Bi Y
      type
      Author
    9. name
      Liu J
      type
      Author
    10. name
      Rahman NA
      type
      Author
    11. name
      Wearne E
      type
      Author
    12. name
      Leighton JK
      type
      Author
    bibliography ids
    1. nci-bib-0f750730217ccab6d6ad3fa4
    book metadata
    content sha256
    4621f480367df540c2d75649fe0d190513199adda6e8bbe926033cb3156c06b8
    document type
    citation
    dois
    1. 10.1158/1078-0432.CCR-22-0873
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35679021
    immutable id
    pubmed:35679021@4621f480367df540c2d75649fe0d190513199adda6e8bbe926033cb3156c06b8
    journal
    abbreviation
    Clin Cancer Res
    issn electronic
    1557-3265
    issn print
    1078-0432
    issue
    19
    name
    Clinical cancer research : an official journal of the American Association for Cancer Research
    nlm unique id
    9502500
    pages
    4173-4177
    volume
    28
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35679021
      provenance
      batch id
      9d150d55960e0c12aada
      provider
      NCBI PubMed ESummary
      record sha256
      0ba5836b404e82775a4fe73edbe6cd789bae1aa938ef92ae5be7203182828a19
      response sha256
      2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
      retrieved at
      2026-09-09T23:48:09.820498+00:00
      publication date
      display
      2022 Oct 3
      precision
      day
      year
      2022
      publication types
      1. Journal Article
      2. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35679021/
      title
      FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

      Preserved source evidence · Not medical advice